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Brain-derived neurotrophic factor (BDNF) has been implicated in the pathophysiology
of schizophrenia, yet its role in the development of specific symptoms is unclear.
Methamphetamine (METH) users have an increased risk of psychosis and schizophrenia,
and METH-treated animals have been used extensively as a model to study the
positive symptoms of schizophrenia. We investigated whether METH treatment in
BDNF heterozygous (HET) mutant mice has cumulative effects on sensorimotor gating,
including the disruptive effects of psychotropic drugs. BDNF HETs and wildtype (WT)
littermates were treated during young adulthood with METH and, following a 2-week
break, prepulse inhibition (PPI) was examined. At baseline, BDNF HETs showed reduced
PPI compared to WT mice irrespective of METH pre-treatment. An acute challenge
with amphetamine (AMPH) disrupted PPI but male BDNF HETs were more sensitive to
this effect, irrespective of METH pre-treatment. In contrast, female mice treated with
METH were less sensitive to the disruptive effects of AMPH, and there were no effects
of BDNF genotype. Similar changes were not observed in the response to an acute
apomorphine (APO) or MK-801 challenge. These results show that genetically-induced
reduction of BDNF caused changes in a behavioral endophenotype relevant to the
positive symptoms of schizophrenia. However, major sex differences were observed in
the effects of a psychotropic drug challenge on this behavior. These findings suggest sex
differences in the effects of BDNF depletion and METH treatment on the monoamine
signaling pathways that regulate PPI. Given that these same pathways are thought to
contribute to the expression of positive symptoms in schizophrenia, this work suggests
that there may be significant sex differences in the pathophysiology underlying these
symptoms. Elucidating these sex differences may be important for our understanding
of the neurobiology of schizophrenia and developing better treatments strategies for the
disorder.
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INTRODUCTION
Schizophrenia is a debilitating neuropsychiatric disease, and
despite numerous factors being associated with disease risk and
pathophysiology, the etiology of the illness is poorly understood.
This gap in our knowledge has hindered the development of new
treatment strategies that target the positive, negative and cogni-
tive symptoms on the illness. Altered brain-derived neurotrophic
factor (BDNF) signaling has been associated with schizophrenia
through post-mortem, blood biomarker and genetic association
studies (Angelucci et al., 2005). Post-mortem studies have con-
sistently shown reduced BDNF expression in the hippocampus
and dorso-lateral prefrontal cortex (DLPFC) of patients with
schizophrenia, two brain regions that are highly implicated in the
pathophysiology of the disorder (Takahashi et al., 2000; Weickert
et al., 2003; Hashimoto et al., 2005; Wong et al., 2010; Thompson
Ray et al., 2011). These findings have lead to numerous stud-
ies aiming to asses peripheral BDNF as a biomarker for the
illness, and a recent meta-analysis found a moderate decrease in
blood BDNF levels in drug-naïve and medicated schizophrenia
patients (Green et al., 2011). Others have shown an associa-
tion between the BDNF gene single nucleotide polymorphism
(SNP) val66met and schizophrenia in some populations (Neves-
Pereira et al., 2005; Gratacos et al., 2007). Although this has not
been replicated in other population and genome-wide association
studies, other groups have shown associations in patients with
schizophrenia between the SNP and age of onset (Numata et al.,
2006; Chao et al., 2008; Zhou et al., 2010), cognitive performance
(Ho et al., 2006; Rybakowski et al., 2006; Kebir et al., 2009; Lu
et al., 2012), and neuroimaging measures (Szeszko et al., 2005;
Koolschijn et al., 2010; Smith et al., 2012). Interestingly, there are
major sex-differences in the age of onset of schizophrenia and
also symptom severity, with males showing earlier onset of dis-
ease and greater cognitive deficits (Hafner et al., 1993; Goldstein
et al., 1998). It has recently been proposed that altered BDNF
signaling in the disorder may contribute to these sex differences
(Hill, 2012).
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BDNF is important for neuronal differentiation and survival
during early brain development, and has further roles in synap-
tic plasticity in the adult brain, however it is unclear how altered
BDNF signaling may contribute to disruption of behavior related
to the symptoms observed in schizophrenia. BDNF knock-out
mice have a severe phenotype and typically do not survive beyond
3 weeks of age, whereas the BDNF heterozygous (HET) mice
exhibit a more subtle phenotype and normal survival. We have
previously shown that BDNF protein levels are reduced by a third
to a half of WT expression levels throughout the brain in BDNF
HETs (Hill and van den Buuse, 2011). This is similar to the
reduction of BDNF protein observed in schizophrenia (Weickert
et al., 2003), therefore these animals can be used as a model to
examine the role of BDNF in behaviors related to schizophrenia.
Indeed, this strain has been extensively characterized during the
last decade in behavioral endophenotypes related to psychiatric
disorders, with most studies showing little disturbance in baseline
behavior, making them appropriate for experiments examining
the effects of additional environmental manipulations. We have
recently shown that male BDNF HETs show an increased vul-
nerability to the effects of young-adult corticosterone treatment,
which caused a deficit in short-term spatial memory in a Y-maze
task with parallel alterations in hippocampal NMDA receptor
subunit expression (Klug et al., 2012). Others have demonstrated
that BDNF HETs show altered sensitivity to the effects of stress
and antidepressant treatments in paradigms testing anxiety and
depressive-like behavior (Saarelainen et al., 2003; Duman et al.,
2007, 2008; Ibarguen-Vargas et al., 2009). These findings sup-
port the notion that reduced BDNF expression, as is observed in
schizophrenia, may alter an individual’s sensitivity to the effects
of other environmental risk factors (Caspi and Moffitt, 2006).
Drug abuse is one environmental factor that has been associ-
ated with increased risk of neuropsychiatric illnesses (Gururajan
et al., 2012), and methamphetamine (METH) users have an
increased risk of psychosis and schizophrenia (McKetin et al.,
2010; Callaghan et al., 2012). While not all users will experience
long-lasting psychosis, those who do tend to have an earlier age
of first METH use, and increased familial risk of schizophrenia
(Chen et al., 2003, 2005). These findings suggest that young adult-
hood may be a period of particular vulnerability, and that genetic
factors also contribute to an individual’s risk. One group has
shown that the BDNF val66met SNP is associated with psychosis
in Chinese METH users but not those from other ethnicities (Sim
et al., 2010). Interestingly, this study found that METH depen-
dence was associated with the val allele, while psychosis in METH
users was associated with the met allele that has previously been
linked with schizophrenia risk and disease outcomes. In animal
models, BDNF expression has been shown to change following
acute and repeated treatment with amphetamines (Le Foll et al.,
2005; Angelucci et al., 2007), and rodent models with geneti-
cally modified expression of BDNF, including BDNF HETs, show
altered sensitivity to a number of stimulant drugs (Hall et al.,
2003; Bahi et al., 2008; Saylor and McGinty, 2008).
The aim of the current study was to examine the long-term
effects of chronicMETH treatment in BDNFHETs during young-
adulthood on a behavioral endophenotype related to the pos-
itive symptoms of schizophrenia, prepulse inhibition (PPI) of
the acoustic startle reflex. We predicted that METH adminis-
tration in an escalating dosing regime during young adulthood
would cause a disruption of PPI in adulthood, and given that
BDNF has been implicated in the actions of METH previously,
that BDNF HETs may respond to this treatment differentially.
Given that BDNF levels are reduced in schizophrenia, BDNF
HETs may be more likely to show a disturbance of PPI follow-
ing METH exposure. PPI is a measure of sensorimotor gating, a
form of information processing that is disrupted in patients with
schizophrenia. Reduced PPI in schizophrenia is associated with
thought disorder and functional impairment (Perry and Braff,
1994; Swerdlow et al., 2006), and deficits in PPI are considered
to be a valid endophenotype related to the positive symptoms of
the illness. PPI is one of the most widely used behavioral tests in
mouse models related to schizophrenia, due to its high construct
validity across species compared to other behavioral measures
relevant to the disorder (Powell et al., 2009). The neurophar-
macology of PPI has been characterized extensively in humans
and rodent models, implicating dopaminergic, serotonergic, and
glutamatergic signaling pathways (Geyer et al., 2001). Acute chal-
lenge with psychotropic drugs that target these neurotransmitter
systems causes a disruption of PPI similar to what is observed in
schizophrenia (van den Buuse, 2010). Our laboratory and oth-
ers routinely use the psychotropic drugs amphetamine (AMPH),
apomorphine (APO), and MK-801 to investigate the neurophar-
macology of behavioral endophenotypes relevant to the positive
symptoms of schizophrenia (Chavez et al., 2009). Acute AMPH
can mimic behavioral changes observed in schizophrenia, largely
due to increasing subcortical release of dopamine, similar to
what is thought to cause psychotic episodes in schizophrenia
(Abi-Dargham et al., 1998). Challenge with the D1/D2 receptor
agonist APO can also be used to further investigate dopamin-
ergic regulation of PPI. In contrast, the NMDA receptor antag-
onist MK-801 is used as an acute drug challenge model of
the “glutamate hypofunction” hypothesis of schizophrenia (Lahti
et al., 1995). By examining PPI during adulthood at baseline and
following challenge with AMPH, APO and MK-801, we aimed
to understand how BDNF depletion and METH treatment dur-
ing young adulthood may interact to affect the regulation of this
information processing mechanism, and whether neurotransmit-
ter systems related to the pathophysiology of schizophrenia may
be involved in their effects.
RESULTS
EFFECTS OF CHRONIC METH TREATMENT ON BODY WEIGHT AND
LOCOMOTOR ACTIVITY DO NOT DIFFER BETWEEN BDNF HETs
AND WT LITTERMATES
BDNF HETs of both sexes were heavier than their wildtype (WT)
littermates throughout the treatment and behavioral testing peri-
ods [Figure 1B, main effect genotype F(1, 66) = 25.6, p < 0.001].
In addition, during the treatment period female mice treated
with METH did not show the same bodyweight increase as
females treated with saline [first day of treatment vs. last day
of treatment: sex × METH treatment × time-point interac-
tion: F(1, 66) = 4.9, p = 0.031; females only: METH treatment ×
time-point F(1, 33) = 5.7, p = 0.023]. METH-treated female mice
showed significant recovery of bodyweight gain during the weeks
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FIGURE 1 | Experimental timeline, bodyweight change, and locomotor
activity during the treatment period. (A) Mice were treated with saline
or an escalating dosing regime of METH from 6 to 9 weeks of age, i.e.,
during late adolescence/early adulthood. Following a 2-week break, the
animals were tested in four PPI sessions following challenge treatment
with either saline, AMPH, APO, or MK-801 in pseudorandomized order.
(B) Bodyweight at the start or end of the chronic METH/saline treatment
and at the start of PPI testing. BDNF HETs were significantly heavier
than their WT littermates throughout the experiment. At the end of the
chronic treatment period, METH-treated females had reduced bodyweight
compared to saline-treated mice. (C) Locomotor activity recorded at the
end of each subsequent treatment week following morning injections.
METH-treated mice showed significant hyperactivity compared to
saline-treated mice, which increased during the treatment period with
increasing doses of METH administration. This effect did not differ
between the genotypes. ∗∗∗Signifies genotype effect p < 0.001, #signifies
METH × time-point interaction p < 0.05, ###signifies METH × week
interaction p < 0.001.
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following the end of the treatment period despite their body-
weight remaining lower than saline-treated female mice during
the remainder of the experimental period [weekly bodyweight
in the 5 weeks following the end of the treatment period, sex ×
METH treatment interaction F(1, 66) = 4.6, p = 0.037]. There
was no body weight gain delay in male BDNF HETs. Importantly,
METH treatment did not result in bodyweight loss in any of the
groups.
METH administration during the 3-week treatment period
caused significant hyperactivity [Figure 1C, main effect of
METH: F(1, 53) = 208.0, p < 0.001] which became more promi-
nent over the escalating dosing period [METH × treatment week
interaction: F(2, 106) = 189.7, p < 0.001]. At the end of the first
treatment week, there was no effect of the 1mg/kg dose on
locomotor activity. Subsequently, however, the animals showed
increasing levels of hyperactivity in response to the higher doses
of METH administered during the second and third weeks of the
treatment period. There were no differences between male and
female mice or between BDNF HETs and WT mice in the extent
of METH-induced hyperactivity during the treatment period
(Figure 1C).
REDUCED BASELINE PPI AND INCREASED STARTLE REACTIVITY IN
BDNF HETs
Baseline PPI, obtained after injection of saline, was signifi-
cantly lower in BDNF HET mice compared to WT [Figure 2A,
main effect of genotype at 30ms inter-stimulus interval (ISI)
F(1, 66) = 13.1, p = 0.001; 100ms ISI: F(1, 66) = 8.8, p = 0.004].
This effect was independent of METH treatment or the sex of the
animals (Figure 2A).
Average startle across the saline session was significantly higher
in male mice compared to female mice [Figure 2B, main effect
FIGURE 2 | PPI and startle reflex at baseline during saline challenge
sessions. (A) Average PPI across all four PP intensities was significantly
lower in BDNF HETs compared to WT controls. This effect was seen at both
the 30 and 100ms ISI and in both sexes. (B) Average startle responses
across all four startle blocks were significantly increased in BDNF HETs of
both sexes compared to WT controls. ∗∗∗Signifies genotype effect p < 0.005.
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of sex: F(1, 66) = 21.6, p < 0.001]. In addition, baseline startle
was significantly higher in BDNF HETs compared to WT con-
trols [main effect of genotype F(1, 66) = 11.1, p = 0.001]. In male
mice, but not female mice, habituation of startle across the 4
blocks of stimulus-only pulses was slightly accelerated in BDNF
HETs compared to WT controls [data not shown; startle block ×
genotype × sex interaction: F(3, 198) = 4.7, p = 0.005].
SEX-DEPENDENT CHANGES IN THE EFFECT OF AMPH ON PPI AND
STARTLE REACTIVITY
AMPH administration caused a significant disruption of PPI at
both ISIs [Figures 3A–D, main effect, 30ms ISI: F(1, 66) = 124.0,
p < 0.001, 100ms ISI: F(1, 66) = 87.8, p < 0.001]. However, at
the 30ms ISI, there were significant sex-dependent effects of
genotype and METH treatment on the response to AMPH chal-
lenge [AMPH × genotype × sex × prepulse (PP) interaction:
F(3, 198) = 3.5, p = 0.026] and further analysis was therefore
done on the data separated by the sex of the animals. In male
BDNF HET, irrespective of METH pre-treatment, PPI was dis-
rupted to a greater extent by an acute AMPH challenge than
in male WT, particularly at higher PP intensities [Figure 3A,
AMPH × genotype × PP interaction: F(3, 99) = 4.3, p = 0.013,
see also Table 1 for PPI at each PP intensity]. In contrast, female
mice treated with METH showed a reduced sensitivity to the dis-
ruptive effects of an acute AMPH challenge, irrespective of the
genotype [Figure 3B, interaction of AMPH × METH treatment:
F(1, 33) = 4.6, p = 0.039, see alsoTable 2 for PPI at each PP inten-
sity]. At the 100ms ISI, there was a strong trend for reduced
sensitivity to the disruptive effects of AMPH in METH-treated
mice of both sexes (Figures 3C,D, AMPH × METH treatment
interaction p = 0.063).
AMPH administration caused a reduction in startle amplitude
compared to saline [Figures 3E,F, F(1, 66) = 29.9, p < 0.001].
However, this effect of AMPH was reduced by prior METH
treatment in a genotype-specific manner [AMPH × geno-
type × METH treatment interaction F(1, 66) = 4.8, p = 0.031].
Irrespective of the sex of the animals, WT mice treated with
METH did not show a reduction of startle in response to
acute AMPH [WT only: AMPH × METH treatment interaction,
F(1, 36) = 4.5, p = 0.042]. This effect of METH pre-treatment
was not observed in BDNF HETs.
NO MAJOR CHANGES IN THE EFFECTS OF APO IN BDNF HETs OR
FOLLOWING METH TREATMENT
Given that the major effects of AMPH on PPI in mice are thought
to be due to indirect activation of dopaminergic receptors, we
were interested to examine whether the D1/D2 receptor agonist
APO would show similar effects to AMPH. APO caused a signifi-
cant disruption of PPI [Figures 4A–D, at both ISIs: main effect of
APO challenge: F(1, 66) > 85.0, p < 0.001]. In contrast to the sex-
dependent effects of genotype and METH treatment that were
observed in the sensitivity to AMPH, similar effects were not
observed in the response to APO. A minor, but significant change
in APO sensitivity was found as a PP-dependent genotype effect
in male mice, where BDNF HETs were slightly less sensitive to
the effects of APO, but only at the lowest PP intensity examined
[30ms ISI: APO challenge × genotype × sex × PP interaction
F(3, 198) = 3.1, p = 0.037; Table 1, PP2dB only: APO challenge ×
genotype × sex interaction F(1, 66) = 5.0, p = 0.029].
APO also caused a significant reduction in startle response
amplitude (Figures 4E,F). However, this effect was significantly
larger in BDNF HETs [main effect of APO challenge: F(1, 66) =
65.9, p < 0.001; APO × genotype interaction: F(1, 66) = 6.5, p =
0.013], and this effect acted to normalize their startle response
to that of WT animals treated with APO (APO only: main effect
genotype p = 0.154).
NO MAJOR CHANGES IN THE EFFECTS OF MK-801 IN BDNF HETs OR
FOLLOWING METH TREATMENT
MK-801 caused a significant disruption of PPI [at both ISIs: main
effect of MK-801: F(1, 66) > 38.0, p < 0.001]. There were no sig-
nificant changes in the response to MK-801 in BDNF HETs or
following METH treatment (Figures 5A–D). There was no sig-
nificant effect of MK-801 administration on startle amplitudes
(Figures 5E,F).
DISCUSSION
The key findings of the current study were that (1) compared to
WT controls, BDNFHETs showed reduced baseline PPI, irrespec-
tive of METH pre-treatment or the sex of the animals; (2) male
BDNF HETs showed greater sensitivity to the disruptive effects
of an AMPH challenge on PPI at the 30ms ISI, irrespective of
whether they had been pre-treated with METH; (3) female mice
pre-treated with METH showed a relative tolerance to the effects
of AMPH on PPI at the 30ms ISI, irrespective of their genotype.
Thus, there were no interactions between METH treatment and
BDNF depletion on PPI, and no changes were observed in the
PPI-disrupting effects of APO and MK-801 in this model. Startle
response amplitude was higher in BDNF HETs compared to WT
controls, which may be in part due to their increased bodyweight.
AMPH and APO reduced startle reactivity, and there were sig-
nificant genotype effects. METH treatment attenuated the effects
of AMPH on startle in WT mice but not BDNF HETs, while the
effects of APO on startle amplitude were greater in BDNF HETs.
The main aim of the present study was to investigate whether
BDNF deficiency, as present in BDNFHETs, would alter the long-
term effects of chronic METH treatment on PPI. To this end,
we developed a 3-week long escalating METH dosing regime,
using a similar range of doses and frequency of injections to
other escalating METH treatments in mice in the literature
(Chao et al., 2012; Pogorelov et al., 2012). This METH treatment
protocol caused significant hyperactivity during the treatment
period. Unlike many previous studies of the effects of METH on
PPI, behavior was examined after a 2-week break period, as we
aimed to model the long term psychotic symptoms that occur
in some METH users, rather than transient psychosis following
METH which is probably less relevant to the pathophysiology of
schizophrenia. For this reason, it is not surprising that our results
differ from those of previous studies that assessed the immedi-
ate effects of METH on PPI. In experiments where PPI is tested
following repeated pre-treatment with METH, this was found to
disrupt PPI immediately following the final METH treatment.
However METH pre-treated, non-drug challenged controls were
not used in these experiments (Arai et al., 2008; Hadamitzky et al.,
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FIGURE 3 | AMPH-induced disruption of PPI. (A,B) At the 30ms ISI,
following an AMPH challenge, PPI was disrupted in all groups, however the
effect of AMPH was enhanced in male BDNF HETs (A), and was attenuated
in female mice treated with METH (B). (C,D) At the 100ms ISI, following an
AMPH challenge PPI was disrupted in all groups, however this was not
significantly different between the treatment groups. (E,F) Startle responses
following AMPH challenge were reduced, however this effect was not seen in
WT mice treated with METH. ∗Signifies genotype × AMPH × PP interaction
p < 0.05, #signifies METH treatment × AMPH interaction p < 0.05,
$signifies AMPH × genotype × METH treatment interaction p < 0.031.
2011). One group has recently examined the effects of escalat-
ing METH treatment on PPI in mice after a break period, and
found reduced PPI at baseline that could be rescued by electro-
convulsive shock treatment (Chao et al., 2012). However there
are major strain differences in PPI (Willott et al., 2003), and this
study used CD-1 mice which may account for the differences
in our findings. Additionally, while we calculated baseline PPI
from saline challenge sessions, this previous study examined PPI
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Table 1 | Mean PPI ± SEM at each PP intensity during challenge sessions with saline, AMPH, APO or MK-801 treatment in male WT and BDNF
HET mice chronically pre-treated with saline or METH.
30ms ISI 100ms ISI
PP2 PP4 PP8 PP16 Average PP2 PP4 PP8 PP16 Average
MALE WT SALINE
Saline 19.7 ± 7.5 21.4 ± 7.1 44.9 ± 5.5 67.6 ± 3.9 38.4 ± 4.1 24.8 ± 5.0 25.4 ± 4.9 23.9 ± 4.0 50.5 ± 3.8 31.1 ± 3.3
AMPH −15.5 ± 8.8 1.5 ± 7.6 24.9 ±7.6 50.5 ± 5.1 15.3 ± 5.8 −4.9 ± 9.1 −2.7 ± 4.6 12.2 ± 3.8 31.4 ± 4.2 2.0 ± 7.4
APO −28.8 ± 10.5 1.9 ± 5.7 22.8 ± 8.4 46.3 ± 4.9 10.5 ± 4.6 1.5 ± 3.3 −4.2 ± 6.3 13.1 ± 3.3 34.9 ± 4.3 11.3 ± 2.8
MK-801 0.5 ± 7.9 6.7 ± 4.7 23.7 ± 5.3 45.1 ± 4.4 19.0 ± 3.8 −5.6 ± 7.3 −15.4 ± 14.9 −2.4 ± 10.1 31.4 ± 4.2 2.0 ± 7.4
MALE WT METH
Saline 5.1 ± 10.5 23.5 ± 5.9 44.7 ± 5.6 71.7 ± 2.4 36.2 ± 5.0 14.0 ± 6.3 27.9 ± 4.4 37.5 ± 4.1 57.6 ± 4.4 34.2 ± 3.3
AMPH −20.4 ± 13.7 1.0 ± 10.6 38.1 ± 7.8 61.4 ± 4.6 20.0 ± 6.3 −10.8 ± 8.9 6.6 ± 7.5 28.1 ± 5.7 31.8 ± 6.4 7.4 ± 6.5
APO −13.2 ± 12.7 2.5 ± 10.2 24.6 ± 12.6 45.3 ± 11.6 14.8 ± 10.2 −3.6 ± 8.1 4.4 ± 8.6 31.9 ± 8.1 41.1 ± 4.4 18.5 ± 5.8
MK-801 0.6 ± 8.8 15.4 ± 8.5 27.5 ± 7.8 42.6 ± 11.8 21.5 ± 8.2 −8.2 ± 8.5 −6.9 ± 10.2 12.9 ± 9.1 31.8 ± 6.4 7.4 ± 6.5
MALE BDNF HET SALINE
Saline 4.6 ± 6.6 −1.6 ± 7.4 19.3 ± 6.5 48.0 ± 5.2 17.6 ± 4.8 15.5 ± 3.6 15.7 ± 2.9 20.5 ± 4.9 41.4 ± 6.2 23.3 ± 2.9
AMPH −18.4 ± 7.5 −18.1 ± 4.4 −1.6 ± 6.4 24.9 ± 8.2 −3.3 ± 2.3 −8.8 ± 4.9 −9.1 ± 7.8 4.1 ± 5.2 19.7 ± 3.9 1.4 ± 2.4
APO −1.4 ± 5.8 −6.8 ± 8.1 4.3 ± 10.0 21.4 ± 8.4 4.4 ± 6.9 0.7 ± 3.1 −2.5 ± 5.1 12.0 ± 3.6 21.1 ± 5.1 7.8 ± 3.5
MK-801 4.9 ± 6.1 3.1 ± 4.3 9.9 ± 5.5 35.2 ± 6.7 13.3 ± 3.8 −5.9 ± 8.5 3.9 ± 5.6 4.8 ± 9.4 28.3 ± 4.5 7.8 ± 5.1
MALE BDNF HET METH
Saline −3.5 ± 9.5 25.5 ± 4.9 32.2 ± 5.9 58.4 ± 4.4 28.1 ± 3.8 14.5 ± 3.3 23.3 ± 3.9 21.2 ± 4.1 39.3 ± 4.1 24.6 ± 3.0
AMPH −7.3 ± 5.1 −0.9 ± 6.3 −4.2 ± 6.9 36.7 ± 6.5 6.1 ± 4.3 0.0 ± 3.3 3.1 ± 4.0 6.9 ± 5.7 30.9 ± 4.3 10.2 ± 3.3
APO −14.8 ± 9.9 −3.7 ± 6.6 −0.5 ± 12.7 30.7 ± 5.2 2.9 ± 6.0 −5.1 ± 8.4 −6.5 ± 7.2 9.9 ± 6.6 30.8 ± 7.1 7.3 ± 4.5
MK-801 1.2 ± 7.0 −8.2 ± 8.0 4.9 ± 10.7 39.1 ± 5.8 9.3 ± 6.1 −24.2 ± 10.8 −17.5 ± 6.6 −0.2 ± 9.8 25.8 ± 6.4 −4.0 ± 6.5
Table 2 | Mean PPI ± SEM at each PP intensity during challenge sessions with saline, AMPH, APO, or MK-801 treatment in female WT and
BDNF HET mice chronically pre-treated with saline or METH.
30ms ISI 100ms ISI
PP2 PP4 PP8 PP16 Average PP2 PP4 PP8 PP16 Average
FEMALE WT SALINE
Saline 7.8 ± 7.8 28.8 ± 3.7 39.7 ± 5.8 62.0 ± 3.3 34.6 ± 3.5 6.3 ± 7.4 16.2 ± 4.3 31.1 ± 5.1 49.5 ± 3.6 25.8 ± 2.9
AMPH −12.7 ± 7.3 −6.6 ± 5.0 8.5 ± 8.2 29.2 ± 7.6 4.6 ± 5.7 −7.1 ± 6.2 −4.4 ± 7.9 10.4 ± 8.6 27.8 ± 5.5 11.7 ± 3.0
APO −17.1 ± 8.7 −9.5 ± 8.7 18.3 ± 8.8 33.0 ± 5.5 6.2 ± 5.5 −12.6 ± 3.6 2.2 ± 5.9 15.0 ± 5.7 25.5 ± 7.7 7.5 ± 4.1
MK-801 −1.0 ± 4.6 14.4 ± 3.7 16.3 ± 6.2 43.7 ± 5.6 18.4 ± 4.0 −3.5 ± 5.3 9.1 ± 3.3 13.5 ± 4.1 27.8 ± 5.5 11.7 ± 3.0
FEMALE WT METH
Saline 18.4 ± 7.3 27.5 ± 4.5 39.8 ± 5.3 63.2 ± 2.6 37.2 ± 3.9 18.4 ± 4.7 26.8 ± 4.9 35.7 ± 3.5 50.1 ± 4.0 32.8 ± 3.4
AMPH 3.3 ± 6.4 5.9 ± 5.3 37.6 ± 4.2 48.0 ± 3.4 23.7 ± 3.5 3.5 ± 4.2 15.5 ± 5.4 25.3 ± 6.4 47.8 ± 4.5 23.0 ± 3.9
APO 5.4 ± 6.0 9.8 ± 8.1 26.5 ± 7.5 44.2 ± 6.3 21.5 ± 5.4 −3.5 ± 7.7 9.5 ± 3.2 16.9 ± 6.5 38.1 ± 4.7 15.3 ± 3.9
MK-801 11.5 ± 5.3 14.6 ± 6.4 29.8 ±5.4 50.4 ± 3.9 26.6 ± 3.8 3.0 ± 6.1 7.5 ± 4.0 24.9 ± 6.2 43.0 ± 5.2 19.6 ± 4.2
FEMALE BDNF HET SALINE
Saline 13.3 ± 6.3 16.1 ± 4.4 26.0 ± 3.2 40.9 ± 4.9 24.1 ± 3.2 8.3 ± 4.9 18.9 ± 4.5 23.6 ± 3.9 34.8 ± 4.5 21.4 ± 3.2
AMPH −3.5 ± 3.9 −0.1 ± 6.0 5.2 ± 6.3 31.6 ± 4.4 8.3 ± 3.5 5.5 ±3.8 1.5 ± 6.8 8.4 ± 4.4 26.9 ± 3.0 10.6 ± 3.6
APO −25.4 ± 5.7 −12.4 ± 7.0 1.1 ± 8.2 20.2 ± 9.0 −4.1 ± 5.7 −15.0 ± 5.0 2.3 ± 6.7 10.1 ± 7.1 16.9 ± 6.7 3.6 ± 4.1
MK-801 0.4 ± 5.3 12.3 ± 7.6 26.4 ± 6.2 33.9 ± 8.6 18.2 ± 4.6 7.9 ± 3.6 5.5 ± 9.7 7.0 ± 9.2 28.3 ± 6.9 12.2 ± 6.0
FEMALE BDNF HET METH
Saline 21.0 ± 9.5 23.7 ± 8.6 29.4 ± 4.4 58.5 ± 4.0 33.2 ± 5.3 17.0 ± 6.8 19.8 ± 4.7 29.8 ± 3.9 41.4 ± 5.0 27.0 ± 4.2
AMPH 3.7 ± 5.3 16.9 ± 8.2 28.1 ± 5.0 45.7 ± 5.6 23.6 ± 3.7 8.7 ± 4.1 7.9 ± 4.5 20.5 ± 4.8 38.8 ± 4.1 19.0 ± 3.0
APO −8.1 ± 7.9 −6.8 ± 14.5 6.2 ± 8.5 35.0 ± 6.1 6.6 ± 8.2 −11.4 ± 8.5 1.8 ± 7.6 0.6 ± 5.6 20.8 ± 6.6 3.0 ± 6.0
MK-801 8.5 ± 8.5 7.8 ± 8.0 25.5 ± 5.9 44.3 ± 6.2 21.6 ± 5.5 5.5 ± 7.8 4.1 ± 6.5 20.1 ± 4.8 30.4 ± 6.2 15.0 ± 4.7
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FIGURE 4 | APO-induced disruption of PPI. (A–D) PPI following an APO
challenge in male (A) and female (B) mice at the 30ms ISI and male (C) and
female (D) mice at the 100ms ISI. APO disrupted PPI in all groups, and this
was unaffected by BDNF genotype or METH treatment. (E,F) Startle
responses following an APO challenge were reduced; however this effect
was greater in BDNF HETs. *Signifies genotype × APO interaction p < 0.05.
without challenge injections. The acute mild stress associated
with saline injection has previously been shown to reduce PPI in
some mouse strains (Wang et al., 2003), as increased stress hor-
mone levels can alter PPI (van den Buuse et al., 2004). Given these
differences between previous studies and our own, this highlights
the importance of strain, timing following METH treatment and
behavioral testing protocol on the effects of METH in rodent
studies.
Our finding of reduced sensitivity or tolerance to a challenge
dose of AMPH in METH pre-treated females is in contrast to
a previous study, which showed that 1 week pre-treatment with
low dose METH in male CD-1 mice enhanced the effects of
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FIGURE 5 | MK-801-induced disruption of PPI. (A–D) PPI following an
MK-801 challenge in male (A) and female (B) mice at the 30ms ISI and male
(C) and female (D) mice at the 100ms ISI. MK-801 disrupted PPI in all groups,
and this was unaffected by BDNF genotype or METH treatment. (E,F) Startle
response following an MK-801 challenge. There was a trend toward increased
startle reactivity following MK-801 challenge (p = 0.081).
a sub-threshold dose of METH (1mg/kg) to disrupt PPI (Arai
et al., 2008). However, given that our effects of METH were
female-specific it is unclear how this previous result compares to
our finding of tolerance. Furthermore we used a higher challenge
dose of AMPH (5mg/kg), and it may be of interest for future
studies to examine sub-threshold doses of AMPH in our model.
Another key difference between these studies was the inclusion
of a break period in our own study, whereas “sensitization”
was observed immediately followed the METH pre-treatment
period (Arai et al., 2008). The aim of our study was to model
behavioral changes accompanying persistent psychosis follow-
ing METH abuse, whereas the findings of other studies which
examine behavior immediately following METH exposure may
be more reflective of what occurs during transient psychosis
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following METH use (Sato et al., 1992). In contrast to our obser-
vation of tolerance to the effects of AMPH on PPI, in preliminary
studies we have seen long-term locomotor sensitization to an
AMPH challenge in this model (unpublished observations) which
has also been shown previously by others following METH pre-
treatment (Hall et al., 2008). This suggests that METH-induced
plasticity occurring in the pathways regulating PPI is different to
that which occurs in the pathways mediating locomotor sensiti-
zation. This may involve different contributions by monoamine
neurotransmitters in these neural pathways.
The effects of BDNF depletion on PPI have also been exam-
ined previously. For example, in a previous study we did not
observe baseline deficits in PPI in BDNF HETs (Klug et al., 2012).
However, in that study, PPI was examined in animals that had
not previously received chronic injections, and the response of
BDNF HETs following a challenge drug may have been altered
in the PPI paradigm immediately following that unfamiliar mild
stressor. Forebrain restricted knockout of BDNF also resulted in
no changes in baseline PPI in the absence of a challenge injec-
tion (Gorski et al., 2003). Our current observations of reduced
baseline PPI in BDNF HETs irrespective of sex make this a novel
model of sensorimotor gating deficits observed in schizophre-
nia, and future studies should aim to characterize the predictive
validity of this finding by examining the response to current
antipsychotic medications.
The significant effect of BDNF depletion on AMPH-disrupted
PPI, but not on the effects of APO or MK-801, suggests differ-
ential changes in monoaminergic regulation of PPI pathways in
BDNF HETs. Changes in the amount of dopamine release and
reuptake following AMPH challenge, without changes in post-
synaptic receptor expression, may explain the altered sensitivity to
AMPH without major changes in the effects of the D1/D2 recep-
tor agonist APO. Supporting this idea, dopamine levels (measured
by HPLC and in vivo microdialysis) are increased in BDNF HETs
in the caudate putamen, which is also associated with reduced
dopamine transporter (DAT) function (Dluzen et al., 1999; Bosse
et al., 2012). However these studies were conducted inmale BDNF
HETs, and further characterization of the dopaminergic system
in both sexes may be necessary to understand the sex differences
observed in our study. NMDA receptor-mediated regulation of
PPI appears to be unaffected by BDNF depletion and METH
treatment based on our findings of no changes in the sensitivity
to the disruptive effects of MK-801.
It should be noted that, in addition to dopaminergic effects,
changes in serotonergic activity may also play a role in altered sen-
sitivity to the disruptive effects of AMPH on PPI in male BDNF
HETs. Although the psychotropic actions of AMPH appear to
be largely mediated by increasing subcortical dopamine release
(Sulzer et al., 2005), one group has recently reported major con-
tributions of both serotonergic and dopaminergic signaling in the
effects of the active AMPHmetabolite p-hydroxyamphetamine on
PPI in mice (Onogi et al., 2010, 2011). Alterations in serotonin
levels and transporter function have also been described in BDNF
HETs in the CA3 region and ventral hippocampus (Daws et al.,
2007; Deltheil et al., 2008; Guiard et al., 2008). The only study
to assess sex differences in the serotonin system of BDNF HETs
found that males, but not females, showed a deficit in serotonin
transporter clearance rate in the CA3 at 2 months of age (Daws
et al., 2007). Further characterization of the serotonin system in
both sexes of BDNF HETs and in additional brain regions may
clarify the involvement of serotonergic changes in the results that
we have observed. We have previously shown that serotonergic
lesions of the hippocampus in rats disrupt baseline PPI (Kusljic
and van den Buuse, 2004), and it is possible that altered hip-
pocampal serotonin system function in BDNF HETs may also
contribute to changes in baseline PPI in both sexes.
Sex-differences in BDNF signaling have been reported exten-
sively before (Wu et al., 2013), although information about sex-
differences in behavior are somewhat lacking in the analysis of
BDNF HETs. We previously demonstrated in male C57BL/6 mice
that BDNF protein levels in the striatum and frontal cortex are
correlated with serum testosterone levels during adolescent devel-
opment, including a peak in BDNF protein levels at 8 weeks
of age. In female mice, no such relationship was observed with
serum estradiol levels (Hill et al., 2012). These findings suggest
that BDNF is differentially involved in brain development during
this period between the sexes, andmay help to explain sex-specific
changes in BDNF HETs. Specifically, if BDNF plays a differential
role in the development of fronto-striatal circuits in male mice,
this may result in altered monoaminergic regulation of PPI in
male BDNFHETs, leaving these pathways spared in female BDNF
HETs.
BDNF HETs also showed an increase in acoustic startle
response. We observed increased bodyweight in these mice, which
may have contributed to these effects. This has been described
by others in BDNF HETs previously, and was associated with
hyperphagia, hyperglycemia, insulin resistance, and hypoactivity
(Lyons et al., 1999; Duan et al., 2003; Coppola and Tessarollo,
2004). In addition to these baseline startle differences, there were
genotype effects on the action of AMPH and APO on startle
response. Startle response in BDNF HETs was generally more
affected by these drugs, with BDNF HETs being more sensitive to
the effects of APO irrespective of METH pre-treatment, whereas
only WT mice were insensitive to the effects of AMPH following
METH treatment, andMETH-treated HETs responded like saline
pre-treated mice. All of these effects on startle were unaffected by
sex of the animals. Therefore this is unlikely to have contributed
to the changes in PPI that were observed, and in particular the
changes in the sensitivity to the disruptive effects of AMPHwhich
were sex-specific.
Our findings suggest that BDNF is not involved in the long
term effects of METH treatment during young adulthood on
PPI. In contrast, previous work has demonstrated that BDNF is
involved in the acute neuronal response to METH and sensiti-
zation to cocaine (Narita et al., 2003; Bahi et al., 2008). These
differences suggest that BDNF acts in discrete neural pathways
following exposure to stimulants such as METH and cocaine,
and plays a role in selective behavioral changes following these
interventions. Interestingly there were large sex differences in
the independent effects of both BDNF depletion and METH
treatment during young adulthood. Sex differences in the role
of BDNF during adolescent development of the forebrain may
account for some of these effects (Hill et al., 2012). These findings
highlight the need to study both sexes in preclinical research
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into the effects of genetic and environmental factors on behav-
ioral endophenotypes related to schizophrenia, something which
is severely lacking in the current literature on the behavioral
effects of METH. The current findings warrant further investiga-
tion into the sex-differences that result following BDNF depletion
and METH treatment separately, but do not exclude the value
of further research into the interactions between BDNF signaling
and METH-induced dysfunction in other behavioral paradigms,
such as those related to the negative and cognitive symptoms of
schizophrenia.
In summary, we have demonstrated that BDNF depletion and
METH treatment do not have interactive effects on PPI of the
acoustic startle reflex, or its disruption by AMPH, APO, or MK-
801. In contrast, there were sex-specific and independent effects
of these two interventions, particularly on the sensitivity to the
disruptive effects of AMPH. These findings suggest that METH
users may show altered regulation of PPI, and that these effects
may be female-specific and are unlikely to involve altered BDNF
signaling. BDNF HETs of both sexes showed baseline changes in
PPI and startle reactivity, but AMPH disrupted PPI was enhanced
in male mice only. BDNF HETs may be a valuable model for
further research into the effects of BDNF signaling in PPI brain
circuits, and particularly sex-differences, which may contribute
to sensorimotor gating deficits in patients with schizophrenia.
Disrupted sensorimotor gating in schizophrenia is associated with
a significant level of function impairment, and better under-
standing of the molecular pathology in neural circuits that cause
this behavioral disturbance in schizophrenia should assist in the
development of more efficacious therapies.
MATERIALS AND METHODS
ANIMALS
Male and female BDNF HETs and WT littermates were obtained
from a breeding colony at the Florey Institute of Neuroscience and
Mental Health. This colony was originally established with breed-
ers from JAX Mice and Services (Bar Harbour, ME, USA) and
maintained on a C57Bl/6 background. Experimental mice were
weaned at 3 weeks of age and transported to the Mental Health
Research Institute facility for all behavioral experiments. Mice
were housed in individually ventilated cages (IVC, Tecniplast,
Buguggiate, Italy) in same sex groups of 2–6 animals, with
ad libitum access to rodent chow and tap water. The light
period of the circadian cycle was from 07:00 a.m. to 07:00
p.m. and experiments were conducted during the light period.
All experiments were done in accordance with the Australian
Code of Practice for the Care and Use of Animals for Scientific
Purposes set out by the National Health and Medical Research
Council of Australia and were approved by the Florey Institute
of Neuroscience and Mental Health Animal Experimentation
Ethics Committee.
DRUG TREATMENT DURING ADOLESCENCE/EARLY ADULTHOOD
Groups of mice in separate cages were randomly allocated
to receive METH [(±)-METH-HCl, National Measurement
Institute, Pymble, NSW, Australia] or saline vehicle solution
(0.9% sodium chloride, Baxter Healthcare, Old Toongabbie,
NSW, Australia) treatments which commenced at 6 weeks of age.
Numbers in each treatment group were as follows: Male WT
Saline n = 10, Male WT METH n = 9, Male BDNF HET Saline
n = 9, Male BDNFHETMETH n = 9, FemaleWT Saline n = 10,
Female WT METH n = 10, Female BDNF HET Saline n = 8,
Female BDNF HET METH n = 8. Treatments were administered
by intraperitoneal (IP) injection in the mouse housing room
following an escalating dosing regime that has previously been
used to mimic human patterns of abuse [Robinson and Camp
(1987), Figure 1A shows treatment regime in experimental time-
line]. During the first week of treatment, animals received one
daily injection of 1mg/kg METH in the morning (between 8 and
10 a.m) fromMonday to Friday. During the second week of treat-
ment, animals received two daily injections of 2mg/kg METH, in
the morning and afternoon (between 4 and 6 p.m.) fromMonday
to Friday. In the third week of treatment, animals received two
daily injections of 4mg/kg METH, in the morning and afternoon
from Monday to Friday. Every Friday, the acute response of the
animals to METH treatment was assessed in locomotor photo-
cell cages. Vehicle injections matched the frequency of METH
treatments throughout this 3-week period. In all cases, injection
volumes of 10ml/kg were administered using 30 g needles, and
no injections were administered on weekends. Following the end
of the treatment period, mice were left undisturbed for 2 weeks
before commencement of PPI testing.
BEHAVIORAL TESTING DURING TREATMENT: LOCOMOTOR ACTIVITY
To measure the sensitivity of animals to METH administra-
tion during the treatment period, locomotor activity was mea-
sured immediately following treatment administration on Friday
mornings during the 3 week treatment period. Locomotor pho-
tocell arenas [27 × 27 × 40 cm (l × w × h), TruScan, Coulbourn
Instruments, Whitehall, PA, USA] were used to measure locomo-
tor activity. Mice were habituated to the testing arena during two
1 h sessions in the 2 days prior to the first testing session. On
Friday mornings during the treatment period, mice received their
injections in the locomotor testing room and were immediately
placed into photocell arenas. Horizontal activity was recorded for
1 h and was expressed as locomotor distance moved (cm) per
5min interval.
BEHAVIORAL TESTING DURING ADULTHOOD: PREPULSE INHIBITION
Baseline and psychostimulant-induced disruption of PPI was
assessed in mice using a pseudorandomized repeated-measures
paradigm where mice were tested using all challenge drugs with
3–4 days washout between sessions. These drugs were chosen
because they all disrupt PPI albeit via a differential pharmacolog-
ical mechanism of action, i.e., acute dopamine release (AMPH),
non-selective dopamine receptor agonism without effects on
dopamine release (APO) and a non-dopaminergic mechanism
involving NMDA receptor antagonism (MK-801) (Geyer et al.,
2001; van den Buuse, 2010). AMPH (d-amphetamine sul-
fate, 5mg/kg, Sigma, St. Louis, MO, USA), APO [R-(-)-APO
hydrochloride hemihydrate, 5mg/kg, Sigma] and MK-801 [(+)-
MK-801 hydrogen maleate, 0.25mg/kg, Sigma] were used as
challenge drugs in the current study, and these doses have been
used previously to produce a robust disruption of PPI in mice
(Chavez et al., 2009). These were dissolved in saline, with saline
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administered as the control solution. All drugs were administered
IP 10min before the start of the PPI session.
All mice were tested for startle, startle habituation and PPI
of startle using previously published protocols (van den Buuse
et al., 2009). Briefly, we used San Diego Instruments (San Diego,
CA, USA) SRLab automated startle boxes and the PPI session
consisted of 104 trials, taking approximately 36min to complete.
The protocol commenced with 3min of 65 dB background noise.
The session started and ended with a block of 8 trials delivering
only a 115 dB pulse. Together with 16 pseudorandomly delivered
pulse-alone stimuli during the main component of the session,
responses to these startle pulses were used to construct startle
habituation curves. PP-pulse trials consisted of a 115 dB pulse,
preceded either by 30 or 100ms by a PP of 2, 4, 8, or 16 dB
over the 65 dB background noise (total SPL 67, 69, 73, or 81 dB).
PPI was calculated as the difference between the median response
to PP-pulse trials and the median response to pulse-alone trials,
expressed as a percentage of the median response to the pulse-
alone trials. The session also included 8 trials during which no
sound stimulus was delivered, in order to check for non-specific
movements.
STATISTICAL ANALYSES
All data were expressed as mean ± standard error of the mean
(SEM). Differences within and between groups were analyzed by
analysis of variance (ANOVA) with repeated measures (Systat,
version 9, SPSS Inc., USA). For analysis of PPI data, PP intensity,
startle block, ISI and acute drug challenge were included as
within-group, repeated measures factors, while METH treatment,
genotype, and sex were included as between-group factors. The
effect of a drug challenge to disrupt PPI was considered signif-
icantly different when there was a drug challenge × between
group factor interaction, using a repeated measures ANOVA that
included data from saline and drug challenge sessions. For anal-
ysis of locomotor activity during the treatment period, week
of treatment period and time during session were included as
within-group, repeated measures factors, while METH treat-
ment, genotype, and sex were included as between-group factors.
When p < 0.05, differences were considered statistically signif-
icant. The Greenhouse-Geisser Epsilon correction was applied
when multiple repeated measures were compared in the same
ANOVA test.
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